What does Pierian Dx do?

Pierian Dx, is a leading provider of genomic software and services which enables data driven personalized medicine. The company helps clinical labs in delivering patient specific diagnosis and treatments based on individual’s DNA. The company’s genomics software platform, Clinical Genomicist Workstation provides the leading data driven workflow for academic medical centers, health systems and commercial labs for improving patient outcomes via more precise genomic analysis, interpretation and reporting. The company’s software platform enables the clinical labs to deliver on the promise of personalized medicine by providing comprehensive clinical insights for constitutional disorders and somatic cancer. The company’s software does it by providing a highly streamlined workflow a extensive, constantly updated and curated knowledgebase.

How much Pierian Dx was funded?

Pierian Dx raised $9.25M in Series A on January 7, 2016 from Health Catalyst, Inova Translational Medicine Institute and ARUP Laboratories.

What is next for Pierian Dx?

The company’s latest funds will be used for expanding its lead as a pioneer in NGS- Next Generation Sequencing software and services. The funding will accelerate product development and sales expansion, marketing and operations efforts. The company’s CEO Ted Briscoe said that the company is excited to have the HCCM lead its investment syndicate.

Charles Boorady said HCCM is on a mission of investing in healthcare companies which improve the quality of care and reducing the costs. It partners with the nest platform which are sustainable models and have experienced management teams and Pierian Dx fits this description well. The company will become the gold standard for genetic data interpretation and reporting.

More about Pierian Dx

The company was founded in 2014. It has its headquarters in St Louis, Missouri.  This company helps the health systems, commercial labs and academic medical centres in delivering patient specific diagnosis and treatments based on an individual’s DNA. The company has regularly enhanced with new patient, research and clinical data.